Karatasakis George, Leontiadis Evangelos, Peristeri Ioulia, Manginas Athanassios, Goussetis Evgenios, Graphakos Stelios, Papadakis Emmanouil, Cokkinos Dennis V
1st Department of Cardiology, Onassis Cardiac Surgery Center, 356 Syngrou Avenue, 17674 Athens, Greece.
Eur J Echocardiogr. 2010 Jun;11(5):440-5. doi: 10.1093/ejechocard/jep235. Epub 2010 Mar 22.
We sought to evaluate the efficacy of intracoronary infusion of selected bone marrow stem cells (BMSCs) in patients with remote, anterior non-viable MI by the use of tissue Doppler imaging.
We infused selected CD133+ and CD133-CD34+ BMSCs in 10 patients enrolled in the study. Peak systolic strain rate, maximum strain during the cardiac cycle (epsilon(max)), strain during ejection time (epsilon(et)), and post-systolic strain (epsilon(ps)) were measured. Peak systolic strain rate (-0.69 +/- 0.2 vs. -1.15 +/- 0.27, P = 0.001), epsilon(max) (-9.87 +/- 3.30 vs. -15.57 +/- 5, P = 0.006), and epsilon(et) (-7.45+/-2.86 vs. -10.92 +/- 4.45, P = 0.015) improved significantly during the rest study 6 months after cell infusion. Low-dose inotropic challenge also showed significant improvement of longitudinal deformation indices in the follow-up study. Global ejection fraction did not improve significantly after cell therapy.
Intracoronary infusion of selected BMSCs in patients with remote, anterior, non-viable myocardial infarction is safe and leads to improvement of longitudinal deformation indices 6 months after the infusion.
我们试图通过组织多普勒成像评估冠状动脉内输注特定骨髓干细胞（BMSCs）对陈旧性前壁心肌梗死患者的疗效。
我们对10名参与研究的患者输注了特定的CD133 +和CD133 - CD34 +骨髓干细胞。测量了收缩期峰值应变率、心动周期中的最大应变（ε(max)）、射血期应变（ε(et)）和收缩后期应变（ε(ps)）。细胞输注后6个月的静息研究期间，收缩期峰值应变率（-0.69±0.2对-1.15±0.27，P = 0.001）、ε(max)（-9.87±3.30对-15.57±5，P = 0.006）和ε(et)（-7.45±2.86对-10.92±4.45，P = 0.015）显著改善。低剂量的强心刺激在随访研究中也显示纵向变形指标有显著改善。细胞治疗后整体射血分数没有显著改善。
对陈旧性前壁心肌梗死患者冠状动脉内输注特定的骨髓干细胞是安全的，并在输注后6个月导致纵向变形指标的改善。
